Soleno Therapeutics' DCCR Tablets Show Results in Long-Term Prader-Willi Syndrome Study
Portfolio Pulse from Benzinga Newsdesk
Soleno Therapeutics, Inc. (NASDAQ:SLNO) announced positive top-line results from the randomized withdrawal period of Study C602, a long-term treatment study of DCCR (Diazoxide Choline) Extended-Release tablets for the treatment of Prader-Willi syndrome (PWS).
September 26, 2023 | 11:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Positive results from Soleno Therapeutics' long-term study of DCCR tablets for Prader-Willi syndrome treatment could potentially boost the company's stock.
Positive clinical trial results often lead to increased investor confidence, which can drive up the stock price. Given that the news is directly about Soleno Therapeutics and its product, the relevance and importance are high.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100